Stockscreener 앱 받기
17.84
10.19%
1.65
시간 외 거래:
17.84
전일 마감가:
$16.19
열려 있는:
$16.23
하루 거래량:
3.26M
Relative Volume:
0.85
시가총액:
$13.76B
수익:
$220.00K
순이익/손실:
$-746.08M
주가수익비율:
-17.71
EPS:
-1.0074
순현금흐름:
$-211.81M
1주 성능:
+5.25%
1개월 성능:
-7.47%
6개월 성능:
-30.99%
1년 성능:
-6.11%
1일 변동 폭
$16.23
$17.95
1주일 범위
$15.62
$17.95
52주 변동 폭
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.84 | 12.05B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Biotech Alert: Searches spiking for these stocks today - TipRanks
(SMMT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Summit C-Suite Risks Success, Akeso Wins Either Way (OTCMKTS:AKESF) - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - MSN
Is Summit Therapeutics Inc. building a consolidation baseMarket Rally & Weekly Top Stock Performers List - newser.com
What MACD and RSI say about Summit Therapeutics Inc.Gap Up & Weekly Chart Analysis and Trade Guides - newser.com
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT) - Seeking Alpha
Has Summit Therapeutics Inc. found a price floorJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Wolfe Research Initiates Coverage of Summit Therapeutics (SMMT) with Peer Perform Recommendation - Nasdaq
Summit Therapeutics at Jefferies London: Strategic Progress in Cancer Trials By Investing.com - Investing.com Canada
Wolfe Research Initiates Coverage on SMMT with 'Peer Perform' Ra - GuruFocus
Transcript : Summit Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 03 - MarketScreener
What institutional flow reveals about Summit Therapeutics Inc.GDP Growth & Real-Time Buy Zone Alerts - newser.com
News impact scoring models applied to Summit Therapeutics Inc.Options Play & Technical Pattern Alert System - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
Should you hold or exit Summit Therapeutics Inc. nowJuly 2025 Highlights & Free Verified High Yield Trade Plans - newser.com
Is Summit Therapeutics Inc. stock a safe haven assetForecast Cut & Short-Term High Return Ideas - Fundação Cultural do Pará
Analyzing Summit Therapeutics Inc. with risk reward ratio chartsWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Can Summit Therapeutics Inc. hit a new high this monthInsider Selling & Weekly Return Optimization Plans - newser.com
Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial - Insider Monkey
Responsive Playbooks and the SMMT Inflection - news.stocktradersdaily.com
Summit and Akeso ivonescimab’s shows significant OS benefit - The Pharma Letter
Clear Street Remains a Buy on Summit Therapeutics (SMMT) - The Globe and Mail
Insiders Are Buying These 3 Stocks Hand Over Fist - AOL.com
Summit Therapeutics Reports Positive Phase III Trial Results - MSN
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Placera.se
Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer - MarketScreener
Summit Therapeutics Inc Reports Positive Phase III Trial Results - TradingView
[8-K] Summit Therapeutics Inc. Reports Material Event | SMMT SEC FilingForm 8-K - Stock Titan
Summit (NASDAQ: SMMT): ivonescimab combo OS 16.8 vs 14.1 mo in EGFRm NSCLC - Stock Titan
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.13%
4.32%
자본화:
|
볼륨(24시간):